Panion’s epilepsy drug candidate shows positive initial results in a long-term study by CombiGene
Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene’s drug vector CG01. Initial results from CombiGene’s long-term study in rats was released yesterday in a message, which is highly relevant for Panion’s development of the product for epilepsy in dogs. Professor Merab Kokaia from Lund University, who has lead the study, expresses his joy over the results. http://combigene.com/2/wp-content/uploads/2017/12/CombiGene_PM_20171206_long-term_study.pdf He explains that the study analyses three different parameters related to the epileptic brain. ·